The influence of sibutramine therapy on the body composition and metabolic characteristics of the patients presenting with exogenous constitutional obesity

Vlasova Iu.Iu.; Ametov A.S.

doi:https://doi.org/

Vlasova Iu.Iu.

Federal'noe agentstvo po zdravookhraneniiu i sotsial'nomu razvitiiu;
GOU DPO Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia, Moskva

Ametov A.S.

Federal'noe agentstvo po zdravookhraneniiu i sotsial'nomu razvitiiu;
GOU DPO Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia, Moskva

The influence of sibutramine therapy on the body composition and metabolic characteristics of the patients presenting with exogenous constitutional obesity

Authors:

Vlasova Iu.Iu., Ametov A.S.

More about the authors

Journal: Problems of Endocrinology. 2012;58(1): 34‑38

Read: 55961 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Vlasova IuIu, Ametov AS. The influence of sibutramine therapy on the body composition and metabolic characteristics of the patients presenting with exogenous constitutional obesity. Problems of Endocrinology. 2012;58(1):34‑38. (In Russ.)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Comparative analysis of the state of the microvasculature of the oral mucosa in persons with metabolic syndrome in the aspect of orthopedic dental rehabilitation. Stomatology. 2024;(6-2):15-22

Chronic inflammation in case of obesity-associated diseases. Russian Journal of Preventive Medicine. 2025;(1):115-121

Identification of prognostic significant markers of early diagnosis of obesity and metabolic disorders. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6-2):71-79

Possibilities of using meldonium as part of complex therapy in patients with ischemic heart disease and chronic heart failure combined with obesity. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):53-60

Safety assessment of bariatric surgery in the Russian Federation according to the Russian National Bariatric Registry. Endoscopic Surgery. 2025;(1):5-14

Adipocytokines as a predictor of the risk of adverse outcomes in patients with coronary heart disease and abdominal obesity after percutaneous coronary intervention. Russian Journal of Preventive Medicine. 2025;(2):38-45

Characteristics of the myocardial structural and functional parameters depending on the metabolic phenotype of the Arkhangelsk city residents. Russian Journal of Preventive Medicine. 2025;(2):53-60

Serum concentrations of irisin, erythroferrone, myostatin and interleukin-6 in obese patients depending on the presence of sarcopenia. Russian Journal of Preventive Medicine. 2025;(2):67-73

The effectiveness evaluation of a single primary motivational counseling in patients with obesity and cardiovascular diseases. Russian Journal of Preventive Medicine. 2025;(2):80-86

Analysis of the infrastructure for physical activity of the population and its association with obesity. Russian Journal of Preventive Medicine. 2025;(3):46-52

Abstract:

The treatment of 36 patients suffering exogenous constitutional obesity (ECO) with sibutramine during 12 weeks resulted in the substantial reduction of body weight, waist circumference (WC), hip circumference (HC), and waist-to-hip ratio (WHR). Simultaneously, the total cholesterol level in the blood decreased. The reduction in the body weight had positive effect on carbohydrate metabolism. Medicamental treatment of obesity caused a drop in systolic arterial pressure and a substantial change in the body composition. Specifically, percentage of both total and visceral fat as well as basal metabolism decreased, water retention in the body increased while the muscular mass remained unaltered. It is concluded that the introduction of Sibutramine into the combined treatment of exogenous constitutional obesity effectively promotes the reduction of the body weight, improvement of the body composition and metabolic characteristics.

Keywords:

obesity

sibutramin

Authors:

Vlasova Iu.Iu.

Federal'noe agentstvo po zdravookhraneniiu i sotsial'nomu razvitiiu;
GOU DPO Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia, Moskva

Ametov A.S.

Federal'noe agentstvo po zdravookhraneniiu i sotsial'nomu razvitiiu;
GOU DPO Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia, Moskva

Close metadata

References:

World Health Organization Obesity and overweight facts (udalennyi dostup: http://www.who.int/mediacentre/factsheets/fs311/en/index.html] (accessed July 2005).
Butrova S.A. Sibutramin (meridia) v lechenii ozhireniya: opyt primeneniya v Rossii. Klin farm i ter 2001; 10: 2: 71-74.
Rang H.P., Dale M.M., Ritter J.M., Moore P.K. Pharmacology (5th Ed.). Lovington (Edinburg) 2004; 394-403.
Cummings D.E., Schwartz M.W. Genetics and pathophysiology of human obesity. Ann Rev Med 2003; 54: 453-471.
Kharkevich D.A. Farmakologiya. M 2004; 350-351, 497-500.
Kopelman P.G., Grace C. New thoughts on managing obesity. Gut 2004; 53: 7: 1044-1053.
Labib M. acp Best Practice No 168. The investigation and management of obesity. J Clin Pathol 2003; 56: 1: 17-25.
Murphy K.G., Bloom S.R. Gut hormones in the control of appetite. Exp Physiol 2004; 89: 5: 507-516.
Payer J., Hainer V., Ondrejka P. et al. Sibutramin in obesity treatment (multicenter, open, prospective 12-month-long study) J Vnitr Lek 2004; 50: 11: 825-829.
Finer N. Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors. Eur Heart J 2005; Suppl 7: Suppl L: L32-L38.
Hainer V., Kabrnova K., Aldhoon B. et al. Serotonin and norepinephrine reuptake inhibition and eating behavior. Ann NY Acad Sci 2006; 1083: 252-269.
Luque C.A., Rey J.A. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 2002; 440: 2-3: 119-128.
Phelan S., Wadden T.A. Combining behavioral and pharmacological treatments for obesity. Obes Res 2002; 10: 6: 560-574.
Kennedy G.C. The role of depot fat in the hypothalamic control of food intake in the rat. Proc R Soc Lond B Biol Sci 1953; 140: 901: 578-596.
Bray G.A., Ryan D.H., Gordon D. et al. A double-blind randomized placebo-controlled trial of sibutramine. Obestet Res 1996; 4: 3: 263-270.
James W.P, Astrup A., Finer N et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 9248: 2119-2125.
Philip W., James T., Ian D. et al. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. N Engl J Med 2010; 363: 905-917.
Bjorntorp P., Holm J., Rosmond R. Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus. Diabet Med 1999; 16: 5: 373-383.
Dedov I.I., Mel'nichenko G.A. Ozhirenie. Rukovodstvo dlya vrachei. M 2004; 52-53.
Harris R.B., Kasser T.R., Martin R.J. Dynamics of recovery of body composition after overfeeding, food restriction or starvation of mature female rats. J Nutr 1986; 116: 12: 2536-2546.
Gibbs J., Young R.C., Smith G.P. Cholecystokinin decreases food intake in rats. J Comp Phys Psychol 1973; 84: 3: 488-495.